Entod Pharma unveils AI bio-engineered collagen skin serum

Mumbai-based Entod Pharmaceuticals has announced the launch of COLLADERM™️, a global breakthrough in regenerative skincare. Officially unveiled at the 54th National Conference of the Indian Association of Dermatologists, Venereologists & Leprologists (DERMACON 2026), COLLADERM™️ introduces a first-in-class transdermal collagen gel serum designed for deep, structural skin regeneration. The product is now officially available in the market from February onwards.

Developed in the UK using advanced AI-driven bio-engineering and exclusively licensed to Entod Pharmaceuticals for the Indian market, the COLLADERM™️formulation has been further optimised at the company’s DSIR-approved R&D centre in India. The product has been refined to address Indian skin biology, climatic conditions, and real-world clinical requirements.

Collagen plays a central role in skin resilience, hydration, elasticity, and visible firmness. However, conventional collagen formats face practical limitations: injectable options are procedure-based and costly, oral collagen absorption can be inconsistent, and topical collagen often struggles to penetrate beyond the skin surface. COLLADERM™️ is engineered to overcome these barriers through advanced collagen bio-engineering and transdermal delivery science, supporting visible skin renewal, enhanced hydration, improved firmness, and a rejuvenated appearance.

At the core of COLLADERM™️ is Entod’s proprietary Quattro Collagen System, which integrates Type III and Type XVII Recombinant Vegan Collagens (RVC), previously unavailable in India, in both high and low molecular weights for multi-depth biological action.

This system is supported by TRANSCELLAR™️, a cold-processed transdermal liposomal delivery platform engineered to enhance penetration and cellular uptake. The formulation is further enriched with hyaluronic acid, glycerin, and vitamin C, supporting hydration, permeability, and collagen co-activation.